AbbVies global product sales reduce 1.

Start of our HCV therapy. AbbVie is issuing diluted earnings-per-share guidance for the full-year 2014 of $3.00 to $3.10 on an modified basis, or $2.63 to $2.73 on a GAAP basis. The company's 2014 adjusted diluted earnings-per-share assistance excludes $0.37 per share of intangible asset amortization expenditure and other specified items primarily associated with certain separation-related costs and ongoing restructuring activities.. AbbVie’s global product sales reduce 1.8 percent to $5.111B in fourth quarter 2013 AbbVie today announced financial results for the fourth quarter and full calendar year ended Dec. 31, 2013. We are pleased with AbbVie's performance in our first full calendar year as an unbiased biopharmaceutical firm, said Richard A. Gonzalez, chairman and ceo, AbbVie.Each spring, vast amounts of migratory birds arrive from countries further south, the researchers estimated. These birds likely bring a lot more than 19 million neotropical ticks to the United States, the scholarly study authors explained. However the ticks have little to no chance of surviving once they reach america, the authors suggested. AMERICA doesn’t offer the exotic ticks the features they need to survive, reproduce and spread, study co-author Sarah Hamer said in a journal news release. Hamer is an associate professor in the department of veterinary integrative biosciences at the faculty of Veterinary Medicine and Biomedical Sciences at Texas A&M University in University Station, Texas.